Satraplatin
Satraplatin (BMS-182751, BMY-45594, JM-216) is a platinum-based antineoplastic agent that binds to guanine residues in DNA, inhibits DNA replication and transcription, leads to subsequent apoptosis; shows similar cytotoxicity and pattern of cytotoxicity to cisplatin against human ovarian carcinoma cell lines (IC50=1.7 uM) ; shows antitumor selectivity far superior to cisplatin, carboplatin, or tetraplatin in vivo; orally active.Chemotherapeutic Agents, Phase 2 Clinical (In Vitro) :Satraplatin needs to avoid light in the solution, and it is unstable in the alkaline state but stable in the acidic state.Satraplatin has potent antitumor activity. Satraplatin combined with dichloroacetate (DCA) inhibits UMC-11 cells with an IC50 of 1.36 ± 0.11 μM. Satraplatin also suppresses CDDP-resistant (KB-R) cells (IC50, 7.04 μM), and causes G2/M arrest in KB-R cells.
Product Specifications
CAS Number
129580-63-8
Product Name Alternative
BMS-182751 | BMY-45594 | JM-216
Purity
>98% (HPLC)
Solubility
DMSO: ≥ 33 mg/mL
Smiles
CC (O[Pt] ([NH2]C1CCCCC1) (Cl) (Cl) ([NH3]) OC (C) =O) =O
Molecular Formula
C10H22Cl2N2O4Pt+2
Molecular Weight
500.2816
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Platinum, bis (acetato-κO) amminedichloro (cyclohexanamine) -, (OC-6-43) - (9CI)
Available Sizes
Explore Other Products
Browse additional items from our catalog
NOP14 Lentiviral Vector (Mouse) (CMV) (pLenti-GIII-CMV)
Lentiviral human FRY shRNA (UAS) - Lentiviral human FRY shRNA (UAS, RFP) (25)
